This review focuses on the clinical/pre-clinical evidence relating to MR influence in the myocardium, and the therapeutic potential for MR antagonists in treating or preventing cardiac ischemia and reperfusion injury in both men and women. The gene discussed is NR3C2; the disease is myocardial ischemia.